UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1 -antihistamine–refractory chronic idiopathic urticaria

Journal of allergy and clinical immunology, 2011-09, Vol.128 (3), p.567-573.e1

2011

Volltextzugriff (PDF)

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

Journal of allergy and clinical immunology, 2011-05, Vol.127 (5), p.1309-1310.e1

2011

Volltextzugriff (PDF)

Churg-Strauss Syndrome in Patients Treated With Omalizumab

Chest, 2009-08, Vol.136 (2), p.507-518

2009

Volltextzugriff (PDF)

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

Annals of the rheumatic diseases, 2015-01, Vol.74 (1), p.19-26

2015

Volltextzugriff (PDF)

The Safety and Interpretability of Skin Tests with Omalizumab

Annals of allergy, asthma, & immunology, 2010-12, Vol.105 (6), p.493-495

2010

Volltextzugriff (PDF)

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial

Annals of internal medicine, 2011-05, Vol.154 (9), p.573

2011

Volltextzugriff (PDF)

Development of the Asthma Control Composite outcome measure to predict omalizumab response

Annals of allergy, asthma, & immunology, 2011-09, Vol.107 (3), p.273-280.e1

2011

Volltextzugriff (PDF)

High Prevalence of Skin Test Positivity in Severe or Difficult-to-Treat Asthma

The Journal of asthma, 2006-12, Vol.43 (10), p.745-752

2006

Volltextzugriff (PDF)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis

Annals of the rheumatic diseases, 2016-08, Vol.75 (8), p.1501-1505

2016

Volltextzugriff (PDF)

Allergy, total serum immunoglobulin E, and airflow in children and adolescents in TENOR

Pediatric allergy and immunology, 2010-12, Vol.21 (8), p.1157-1165

2010

Volltextzugriff (PDF)

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H 1-antihistamine–refractory chronic idiopathic urticaria

Journal of allergy and clinical immunology, 2011-09, Vol.128 (3), p.567-573.e1

2011

Volltextzugriff (PDF)

An engineered Trop2/CD3 bispecific antibody for treatment of gastric, pancreatic, and colorectal cancers

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14521-e14521

2023

Volltextzugriff (PDF)

Efficacy and preclinical safety of ARB202, a potential first-in-class anti-CDH17/CD3 bispecific T-cell engager, for treatment of pancreatic and colorectal cancers

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.405-405

2021

Volltextzugriff (PDF)

Phase 1A, first-in-human study of ARB202, bispecific antibody to CDH17 and CD3, in advanced gastrointestinal malignancies expressing CDH17

JCO global oncology, 2023-08, Vol.9 (Supplement_1), p.25-25

2023

Volltextzugriff (PDF)

Nasal polyps: Effects of seasonal allergen exposure

Journal of allergy and clinical immunology, 1994-03, Vol.93 (3), p.567-574

1994

Volltextzugriff (PDF)

Symptom Control and Improved Functioning: The Effect of Omalizumab on Asthma-Related Quality of Life (ARQL)

The Journal of asthma, 2005-01, Vol.42 (10), p.823-827

2005

Volltextzugriff (PDF)

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24months, with a 12-month, double-blind treatment period

Annals of the rheumatic diseases, 2015-01, Vol.74 (1), p.19-26

2015

Volltextzugriff (PDF)

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H sub(1-antihistamine-refractory chronic idiopathic urticaria)

Journal of allergy and clinical immunology, 2011-09, Vol.128 (3), p.567-573.e1

2011

Volltextzugriff (PDF)

A phase, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

Journal of allergy and clinical immunology, 2011-05, Vol.127 (5), p.1309-1310.e1

2011

Volltextzugriff (PDF)

Discrete role for cytosolic phospholipase A(2)alpha in platelets: studies using single and double mutant mice of cytosolic and group IIA secretory phospholipase A(2)

The Journal of experimental medicine, 2002-08, Vol.196 (3), p.349-357

2002

Volltextzugriff (PDF)

Discrete Role for Cytosolic Phospholipase A2α in Platelets: Studies Using Single and Double Mutant Mice of Cytosolic and Group IIA Secretory Phospholipase A

The Journal of experimental medicine, 2002-08, Vol.196 (3), p.349-357

2002

Volltextzugriff (PDF)

Discrete Role for Cytosolic Phospholipase A2α in Platelets

The Journal of experimental medicine, 2002-08, Vol.196 (3), p.349-357

2002

Volltextzugriff (PDF)

Cytosolic phospholipase A2alpha in mouse platelets

Advances in experimental medicine and biology, 2003, Vol.525, p.81

2003

Volltextzugriff (PDF)

Cloning and chromosomal localization of a novel gene-encoding a human β2-integrin α subunit

Gene, 1996-06, Vol.171 (2), p.291-294

1996

Volltextzugriff (PDF)

Confidence-based iterative efficient large-scale stereo matching

Cogent engineering, 2018-01, Vol.5 (1), p.1427676

2018

Volltextzugriff (PDF)

1 – 25 von 2.337

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.940)
Mit Volltextzugriff
(1.925)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.407)
Life Sciences & Biomedicine
(1.125)
Humans
(905)
Female
(538)
Male
(533)
Middle Aged
(348)
Adult
(300)
Biological And Medical Sciences
(283)
Aged
(270)
Medical Sciences
(223)
Animals
(170)
Cardiovascular System & Cardiology
(157)
Cardiac & Cardiovascular Systems
(153)
Technology
(149)
Physical Sciences
(129)
Oncology
(125)
Adolescent
(117)
Aged, 80 And Over
(115)
Retrospective Studies
(113)
Risk Factors
(108)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1 -antihistamine–refractory chronic idiopathic urticaria

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

Churg-Strauss Syndrome in Patients Treated With Omalizumab

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

The Safety and Interpretability of Skin Tests with Omalizumab

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial

Development of the Asthma Control Composite outcome measure to predict omalizumab response

High Prevalence of Skin Test Positivity in Severe or Difficult-to-Treat Asthma

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis

Allergy, total serum immunoglobulin E, and airflow in children and adolescents in TENOR

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H 1-antihistamine–refractory chronic idiopathic urticaria

An engineered Trop2/CD3 bispecific antibody for treatment of gastric, pancreatic, and colorectal cancers

Efficacy and preclinical safety of ARB202, a potential first-in-class anti-CDH17/CD3 bispecific T-cell engager, for treatment of pancreatic and colorectal cancers

Phase 1A, first-in-human study of ARB202, bispecific antibody to CDH17 and CD3, in advanced gastrointestinal malignancies expressing CDH17

Nasal polyps: Effects of seasonal allergen exposure

Symptom Control and Improved Functioning: The Effect of Omalizumab on Asthma-Related Quality of Life (ARQL)

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24months, with a 12-month, double-blind treatment period

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H sub(1-antihistamine-refractory chronic idiopathic urticaria)

A phase, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

Discrete role for cytosolic phospholipase A(2)alpha in platelets: studies using single and double mutant mice of cytosolic and group IIA secretory phospholipase A(2)

Discrete Role for Cytosolic Phospholipase A2α in Platelets: Studies Using Single and Double Mutant Mice of Cytosolic and Group IIA Secretory Phospholipase A

Discrete Role for Cytosolic Phospholipase A2α in Platelets

Cytosolic phospholipase A2alpha in mouse platelets

Cloning and chromosomal localization of a novel gene-encoding a human β2-integrin α subunit

Confidence-based iterative efficient large-scale stereo matching

Suchergebnisse filtern